

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

Katerina Naydenova^{a,1}, Kyle W. Muir^{a,1}, Long-Fei Wu^{a,1}, Ziguo Zhang^a, Francesca Coscia^a, Mathew J. Peet^a, Pablo Castro-Hartmann^b, Pu Qian^b, Kasim Sader^b, Kyle Dent^a, Dari Kimanius^a, John D. Sutherland^{a,2}, Jan Löwe^{a,2}, David Barford^{a,2}, and Christopher J. Russo^{a,2}

^aMedical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom; and ^bMaterials and Structural Analysis, Thermo Fisher Scientific, 5651 GG Eindhoven, The Netherlands

Edited by Eva Nogales, University of California, Berkeley, CA, and approved January 11, 2021 (received for review October 20, 2020)

The RNA polymerase inhibitor favipiravir is currently in clinical trials as a treatment for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite limited information about the molecular basis for its activity. Here we report the structure of favipiravir ribonucleoside triphosphate (favipiravir-RTP) in complex with the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) bound to a template:primer RNA duplex, determined by electron cryomicroscopy (cryoEM) to a resolution of 2.5 Å. The structure shows clear evidence for the inhibitor at the catalytic site of the enzyme, and resolves the conformation of key side chains and ions surrounding the binding pocket. Polymerase activity assays indicate that the inhibitor is weakly incorporated into the RNA primer strand, and suppresses RNA replication in the presence of natural nucleotides. The structure reveals an unusual, nonproductive binding mode of favipiravir-RTP at the catalytic site of SARS-CoV-2 RdRp, which explains its low rate of incorporation into the RNA primer strand. Together, these findings inform current and future efforts to develop polymerase inhibitors for SARS coronaviruses.

COVID-19 | structural biology | cryoEM | T-705 | drug design

The COVID-19 coronavirus pandemic has spurred research into novel and existing antiviral treatments. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA-dependent RNA polymerase (RdRp), crucial for the replication and transcription of this positive-sense single-stranded RNA virus, is a promising drug target for the treatment of COVID-19 (1). Nucleoside analogs, including remdesivir, sofosbuvir, and favipiravir (T-705), have been shown to have a broad spectrum of activity against viral polymerases (2), and are being trialed against SARS-CoV-2 infections (3–5). Recent results of the World Health Organization Solidarity clinical trials indicate that remdesivir, hydroxychloroquine, lopinavir, and interferon treatment regimens appeared to have little or no effect on hospitalized COVID-19 patients, as measured by overall mortality, initiation of ventilation, and duration of hospital stays (6), so insight into the modes of action and mechanisms of current and future drugs for COVID-19 is increasingly important. The structures of the SARS-CoV RdRp (7), the SARS-CoV-2 RdRp (8), and the SARS-CoV-2 polymerase bound to an RNA duplex (9), to RNA and remdesivir (10, 11), and to the helicase nsp13 (12) were all recently determined by electron cryomicroscopy (cryoEM). The suggested modes of action of favipiravir, a purine nucleic acid analogue derived from pyrazine carboxamide (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), against coronaviruses comprises nonobligate chain termination, slowed RNA synthesis, and mutagenesis of the viral genome (13). Here we report the structure of the SARS-CoV-2 RdRp, comprising subunits nsp7, nsp8, and nsp12, in complex with template:primer double-stranded RNA (dsRNA) and favipiravir ribonucleoside triphosphate (favipiravir-RTP), determined by cryoEM at 2.5 Å resolution.

Materials and Methods

General Reagents. Favipiravir (T-705-RTP) was purchased from Santa Cruz; upon receipt, a stock solution of 50 mM T-705-RTP resuspended in 100 mM Tris, pH 7.5 buffer was aliquoted and stored at -80°C . Phosphoramidites were purchased from Sigma-Aldrich or Link Technologies and used without further purification. Acetonitrile and other reagents (cap solutions, deblock solution, and oxidizer solution) were purchased from Sigma-Aldrich. Primer Support 5G for A, G, C, or U (with loading at $\sim 300\ \mu\text{mol/g}$) separately, was purchased from GE Healthcare.

Spectroscopy of Chemical Compounds. Mass spectra were acquired on an Agilent 1200 liquid chromatography–mass spectrometry system equipped with an electrospray ionization source and a 6130 quadrupole spectrometer (chromatography solvents: A, 0.2% formic acid in H_2O and B, 0.2% formic acid in acetonitrile). The ^{31}P -NMR spectra of the T-705-RTP stock solution were acquired using a Bruker Ultrashield 400 Plus operating at 162 MHz.

Protein Purification. A synthetic gene cassette (GeneArts/Thermo Fisher) encoding a SARS-CoV-2 RdRp polyprotein, codon optimized for *Spodoptera frugiperda*, containing nsp5–nsp7–nsp8–nsp12 was cloned, with a C-terminal tobacco etch virus protease cleavage site double StrepII tag, into a pU1 vector for a modified MultiBac baculovirus/insect cell expression (14). The cell pellet was lysed in a buffer of 50 mM Tris-HCl (pH 8.0), 250 mM NaCl, 2 mM MgCl_2 , and 1 mM dithiothreitol, and loaded onto a Strep-Tactin column (Qiagen). The protein complex was eluted in lysis buffer supplemented with 5 mM desthiobiotin. The RdRp was further purified by size

Significance

While the current COVID-19 pandemic continues, the US Food and Drug Administration (FDA) has approved only one drug against the virus—remdesivir. It is a nucleotide analogue inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase; favipiravir is another member of the same class. These nucleoside analogs were originally developed against other viral polymerases, and can be quickly repurposed against SARS-CoV-2 should they prove efficacious. We used cryoEM to visualize how favipiravir-RTP binds to the replicating SARS-CoV-2 polymerase and determine how it slows RNA replication. This structure explains the mechanism of action, and will help guide the design of more potent drugs targeting SARS-CoV-2.

Author contributions: K.N., K.W.M., L.-F.W., J.D.S., J.L., D.B., and C.J.R. designed research; K.N., K.W.M., L.-F.W., Z.Z., F.C., M.J.P., P.C.-H., P.Q., K.S., and K.D. performed research; K.N., K.W.M., L.-F.W., Z.Z., and M.J.P. contributed new reagents/analytic tools; K.N., K.W.M., L.-F.W., Z.Z., F.C., K.D., D.K., J.D.S., J.L., D.B., and C.J.R. analyzed data; and K.N., K.W.M., L.-F.W., J.D.S., J.L., D.B., and C.J.R. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

¹ K.N., K.W.M., and L.-F.W. contributed equally to this work.

² To whom correspondence may be addressed. Email: johns@mrc-lmb.cam.ac.uk, jyl@mrc-lmb.cam.ac.uk, dbarford@mrc-lmb.cam.ac.uk, and crusso@mrc-lmb.cam.ac.uk.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2021946118/-DCSupplemental>.

Published February 1, 2021.

exclusion chromatography on a Superdex 200 16/60 size-exclusion column (Cytiva) in a buffer of 20 mM Hepes (pH 7.5), 200 mM NaCl, 2 mM MgCl₂, and 1 mM Tris(2-carboxyethyl)phosphine (TCEP). Fractions containing nsp7–nsp8–nsp12 were concentrated, flash frozen in liquid nitrogen, and stored at –80 °C as single-use aliquots.

The nsp7 and nsp8 were cloned into the NcoI–NotI, and BamHI–NotI sites of pAcyDuet1 (Millipore), and a pET28 vector modified to encode an N-terminal 6×-His-Sumo tag in frame with the multiple cloning site. Protein expression was pursued in *Escherichia coli* BL21(DE3) Star cells cotransformed with the nsp7 and nsp8 plasmids. Cells were grown in ZY autoinduction media (15) at 37 °C until an optical density at 600 nm of 0.8 was attained, at which point the temperature was reduced to 18 °C, and the incubation was continued overnight. Cells were lysed by sonication in a buffer containing 500 mM NaCl, 20 mM Hepes pH 7.5, 5 mM benzamidine, 20 mM imidazole, and 1 mM TCEP. Proteins were captured with Co²⁺-conjugated resin (Cytiva) for immobilized-metal affinity chromatography (IMAC), eluted in a buffer containing 300 mM NaCl, 20 mM Hepes pH 7.5, 300 mM imidazole, and 1 mM TCEP, followed by overnight cleavage of the 6×-His-Sumo tag by Ulp1, and subjected to subtractive IMAC to remove cleaved tags, uncleaved nsp8, and Ulp1. The nsp7–nsp8-containing solution was then diluted to 150 mM NaCl, further purified via cation exchange, and size exclusion chromatography in assembly buffer (100 mM NaCl, 20 mM Hepes pH 7.5, 2 mM MgCl₂, and 1 mM TCEP; Superdex 200 16/60, Cytiva). Fractions containing nsp7–nsp8 were concentrated, flash frozen in liquid nitrogen, and stored at –80 °C as single-use aliquots.

RNA Synthesis

The RNA template, 5'-rUrUrUrUrCrArUrArCrUrUrArArCrUrCrArCrArUrArGrCrArCrUrG-3', and RNA primer 5'-rCrArGrUrGrCrUrUrArUrGrArGrArUrUrArGrUrArU-3' were prepared by solid-phase synthesis on an ÄKTA oligopilot plus 10 (Cytiva). RNAs were cleaved from the solid support by treating with 4 mL of a 1:1 mixture of 28% wt NH₃/H₂O solution and 33% wt CH₃NH₂/EtOH solution at 55 °C for 30 min; then the silyl protecting groups were removed by treating with 3 mL of 1:1 mixture of triethylamine trihydrofluoride and dimethyl sulfoxide at 55 °C for 90 min. Then, 30 mL of cold 50 mM NaClO₄ in acetone was added to precipitate the RNA product. After centrifugation, the pellet of RNA was dissolved in 5 mL of water and passed through a Sep-Pack C18 Cartridge, 5 g sorbent (Waters). Eluates containing RNA were combined and lyophilized. Mass spectroscopy of the template RNA found *m/z* ([M-7H⁺]) = 1,341.8 (theoretical 1,342.1) and found *m/z* ([M-6H⁺]) = 1,565.6 (theoretical 1,565.9); mass spectrometry of the primer RNA found *m/z* ([M-6H⁺]) = 1,278.6 (theoretical 1,278.9) and found *m/z* ([M-5H⁺]) = 1,534.5 (theoretical 1,534.9).

Annealing of Primer:Template RNA Duplexes. Single-stranded primer and template RNAs (Fig. 1A) were resuspended in deionized and purified H₂O to a final concentration of 200 μM, mixed at an equimolar ratio, and incubated for 5 min in a heat block at 95 °C in Eppendorf tubes with punctured lids. The heat block was then removed from the heating device and allowed to cool to ambient temperature. Annealed dsRNAs were then dispensed as single-use aliquots, flash frozen in liquid nitrogen, and stored at –80 °C.

Assembly of the apo-RdRp Complex. Purified apo-RdRp, assembled as above, was mixed immediately after purification with annealed dsRNA, resuspended in ddH₂O, to a final protein:RNA concentration of 8:20 μM, and was incubated at room temperature for 5 min prior to addition of favipiravir-RTP to a final concentration of 100 μM. Thereafter, complexes were incubated for an additional 30 min at room temperature, prior to another round of centrifugation at 4 °C, transferred to fresh Eppendorf tubes, and used immediately for the preparation of cryoEM grids.

Primer Extension, Drug Incorporation, and Replication Inhibition Assays. All assays (Fig. 1B and C and *SI Appendix, Fig. S1*) were performed at room temperature in assembly buffer. Reaction conditions were designed to approximate, as closely as possible, those employed in production of vitrified electron microscopy (EM) grids. For primer extension assays, 6 μM RdRp (prepared as above) was assembled with 6 μM dsRNA, and mixed with rATP/rGTP (at a final concentration of 500 μM). For drug incorporation assays, RdRp:dsRNA complexes were assembled, mixed with favipiravir-RTP (at final concentrations of 10, 100, and 500 μM), and reactions were allowed to proceed. For replication inhibition assays, RdRp:dsRNA complexes were assembled, and preincubated with favipiravir-RTP (at final concentrations of 10, 100, and 500 μM) for a period of 30 min, prior to addition of rATP/rGTP to a final concentration of 500 μM. This is similar to the assay protocol used for remdesivir in ref. 10. Samples were removed at the indicated time points (0, 30, and 90 min); the reactions were stopped with a 1:1 addition of quenching buffer (98% formamide, 10 mM (ethylenedinitrilo)tetraacetic acid), flash frozen, and stored at –21 °C prior to gel analyses.

Specimen Analysis. The 20% polyacrylamide, 8 M urea gels (0.75 mm thick, 20 cm long) were run at 15 W in Tris–borate–EDTA buffer for 2 h. The RNA gel was stained using SYBR Gold Nucleic Acid Gel Stain (Invitrogen). Fluorescence imaging was performed using an Amersham Typhoon imager (Cytiva).

CryoEM and Atomic Model Building. The complex, prepared as described above, was used at a concentration of 1.3 mg/mL for preparing cryoEM grids. All-gold HexAuFoil grids with a hexagonal array of 280-nm-diameter




Fig. 1. Reconstitution of SARS-CoV-2 RdRp activity and inhibition by favipiravir-RTP (FTP). (A) Sequence of the annealed primer (Upper):template (Lower) dsRNA duplex employed in biochemical assays. (B) Reconstituted SARS-CoV-2 RdRp extends the 24mer primer in the presence (lanes 4 to 6), but not the absence (lanes 1 to 3), of ribonucleotides (rNTPs). A 31mer product is present in lane 6, due to addition of a nontemplated base to the primer strand. (C) Favipiravir is weakly incorporated into the 24mer primer strand (lanes 7 to 15), and suppresses RNA replication by the SARS-CoV-2 RdRp (lanes 16 to 24). Replication, nucleotide incorporation, and replication inhibition assays are representative results of four, six, and six technical replicates, respectively.




Fig. 2. Electron cryomicroscopy of RdRp complexes in the presence of RNA and favipiravir-RTP. (A) Electron cryomicrographs of the reconstituted complexes in unsupported ice (HexAuFoil grid, *Upper*), and on hydrogenated graphene (*Lower*) were used for structure determination. (Scale bar, 500 Å.) (B) This 2D class average from the images of the complex, containing RNA, corresponds to the most frequent orientation of the particles in the thin film of vitreous water. (C) The orientation distribution, with efficiency, E_{od} (23), of the particles used in the reconstruction is plotted on a Mollweide projection, with the most common views on each type of grids marked with gray lines. (D) The Fourier shell correlation (FSC) between the two independent masked half maps, and between the final map and the atomic model, is plotted versus resolution. (E) An overview of the EM map of the polymerase complex is colored by subunit: green, nsp12; blue, nsp7; pink and purple, two copies of nsp8; yellow, template:primer RNA.

holes, 700-nm hole-to-hole spacing, and 330 Å foil thickness were made in-house, and plasma was treated as described in ref. 16. Graphene was grown by chemical vapor deposition, transferred onto all-gold UltrAuFoil R0.6/1 grids (QuantiFoil), and partially hydrogenated following a previously described procedure (17). Grids were rapidly cooled using a manual plunger (18) in a 4 °C cold room. A 3 μ L volume of the protein solution was pipetted onto the foil side of the grid and then blotted from the same side with filter paper (Whatman No. 1) for 11 s to 14 s. The grids were immediately plunged into liquid ethane kept at 93 K in a cryostat (19), and were stored in liquid nitrogen until they were imaged in the electron cryomicroscope.

We acquired electron micrographs from four grids: three HexAuFoil grids (total 52,881 multiframe micrographs) and one partially hydrogenated graphene-coated grid (11,096 multiframe micrographs) (Fig. 2A and *SI Appendix, Table S1*). Other surfaces that were screened during initial specimen preparation included graphene functionalized with amlamine or hexanoic acid and graphene oxide, none of which improved the orientation distribution or yielded two-dimensional (2D) classes indicating degradation of the complex more severe than due to the air–water interface alone. Thus, they were not included in the dataset for high-resolution reconstruction. The high density of foil holes on the HexAuFoil grid, combined with fast imaging by aberration-free image shift and a fast, direct-electron detector (Falcon 4, 248 Hz), allowed us to acquire more than 200 micrographs per hour for 14 consecutive days. The number of micrographs that can be acquired from a single HexAuFoil grid is limited only by the ice contamination rate in the vacuum of the electron microscope, rather than by the number of holes on one grid, even with the fastest available data collection setups.

All data were processed in RELION 3.1 (20), using particle picks imported from crYOLO 1.5 (21) (*SI Appendix, Fig. S2*) with manual retraining of the model. After four rounds of 2D classification, it was clear that the specimen adopted a preferred orientation (Fig. 2B), as previously reported (9). The initial model for 3D refinement was obtained by low-pass filtering a published map of the complex with remdesivir (Electron Microscopy Data Bank accession code EMD-30210) (10) to 20 Å. The uniformity of the particle orientation distribution and the isotropy of the final 3D reconstruction were improved by combining data from HexAuFoil and partially hydrogenated graphene-coated UltrAuFoil EM grids (Fig. 2C). After three rounds of 3D classification, we obtained a 2.5 Å resolution isotropic map of the full complex from 40,828 particles (Fig. 2D and E). A different set of 140,639 particles produced a 2.5 Å resolution map of the nsp12 subunit alone. The remaining 99% of the particles were discarded, as these corresponded to either the overrepresented view of the nsp12 subunit alone or to structurally heterogeneous complexes that did not align to high resolution.

Optical aberrations were refined per grid, the astigmatism was refined per micrograph, and the defocus was refined per particle. Particle movement during irradiation was tracked separately for the graphene and the HexAuFoil datasets, using Bayesian polishing (22). The dataset on graphene shows typical beam-induced motion at the onset of irradiation, whereas this movement is eliminated by the use of the HexAuFoil grids, which provided superior data quality, especially at the onset of irradiation, when the specimen is least damaged. Of the particles contributing to the final 3D refinement, 80% originated from the HexAuFoil grids, and 20% from the partially hydrogenated graphene grid. This was necessary to improve the particle orientation distribution: The efficiency, E_{od} , increased from 0.54 in unsupported ice and 0.57 on partially hydrogenated graphene to 0.68 using a combination of particles from both support surfaces (Fig. 2C) (23). External reconstruction in SIDESPLITTER was performed (24). The atomic model was built based on a previously published atomic model of the nsp12–nsp7–nsp8 complex bound to RNA and remdesivir-RTP (Protein Data Bank [PDB] ID code 7BV2) (10), with manual model building in Coot (25, 26), and real-space refinement in Phenix (27).

Results

To confirm the integrity of the assembled nsp7–nsp8–nsp12 SARS-CoV-2 RdRp complexes, we first performed primer extension activity assays. Consistent with prior publications, we observed efficient primer extension in the presence of natural ribonucleotide triphosphates (rNTPs) (Fig. 1A and B, lanes 4 to 6 and *SI Appendix, Fig. S1*) (8–12). Having verified the activity of the reconstituted RdRp, we then investigated the ability of the enzyme to incorporate favipiravir-RTP into the primer strand. In contrast to natural rNTPs, favipiravir-RTP appears to be a comparably poor substrate, with a low fraction of primer extension observed over the range of experimental conditions tested (Fig. 1C, lanes 7 to 15 and *SI Appendix, Fig. S1*). The formation of larger RNA products observed at later time points (in particular, lanes 12 and 15) must arise through promiscuous base pairing with both uracil and cytosine in the template strand, and is consistent with the reported mutagenicity of favipiravir toward viral genomic RNA in vivo (13, 28, 29). Still, the incorporation efficiency (assessed by the amount of fully extended RNA) of favipiravir is less than that of rNTPs at the same concentration (500 μ M; *SI Appendix, Fig. S1A*, lanes 13 to 15 and 4 to 6, respectively). Finally, we tested whether preincubation with favipiravir-RTP inhibited primer extension in the presence of rNTPs. Despite the low incorporation of favipiravir-RTP observed in primer extension assays, it nevertheless suppressed completion of RNA replication (as judged by the absence of the full 31mer primer extension product) at all concentrations tested, even when rNTPs were added at a considerable excess over the inhibitor (Fig. 1C, lanes 16 to




Fig. 3. Structure of the RdRp complex bound to dsRNA and favipiravir-RTP. (A) The overall structure of the complex is shown, colored by subunit, in the same way as in Fig. 2E. The black lines point to the approximate positions of the catalytic sites, displayed in B and C, where the coloring is by heteroatom, and the EM map is contoured in gray. (B) A pyrophosphate is present at the NiRAN catalytic site of the enzyme, and is coordinated by key conserved residues in this domain. (C) The template:primer RNA duplex is shown, along with favipiravir at the catalytic site (+1) of the polymerase. Hydrogen bonds are indicated.

24 and *SI Appendix, Fig. S1B*). The accumulation of shorter primer extension intermediates at higher concentrations of favipiravir-RTP may indicate premature replication termination. These assays are thus consistent with a previously proposed mode of action of favipiravir-RTP, comprising, in addition to mutagenesis, both slowed RNA synthesis and nonobligate chain termination (13).

To investigate the structural basis of this activity, we determined the structure of the nsp7–nsp8–nsp12 SARS-CoV-2 RdRp complex, in the presence of template:primer RNA and favipiravir-RTP, by cryoEM (Fig. 2 and *SI Appendix, Figs. S2 and S3 and Table S1*). The overall structure of the polymerase complex observed (Fig. 3A and *SI Appendix, Fig. S4*), comprising one nsp12, one nsp7, two nsp8 subunits, and a template:primer RNA, is nearly identical to those previously described (9, 10). With 2.5 Å resolution, and the reduced effects of radiation damage afforded by movement-free imaging (16), the map we determined is suitable for unambiguous atomic model building. We resolved and modeled some additional density in the N-terminal nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of nsp12, including a pyrophosphate and a Mg²⁺ ion (Fig. 3B). These are surrounded by residues which are conserved between SARS-CoV and SARS-CoV-2, including Lys73, Arg116, and Asp218 of the active site of the NiRAN domain (12). However, we did not find density for a possible nucleotide linked to the pyrophosphate at this site. A previous study (11) also observed density consistent with a pyrophosphate, only in a pre-translocated RdRp–RNA complex, but did not attribute it, due to insufficient resolution.

We found that favipiravir and two catalytic Mg²⁺ ions are present at the catalytic site of the complex (Figs. 3C and 4A and *SI Appendix, Fig. S3*). Favipiravir is stacked onto the 3' nucleotide of the primer strand, and forms a noncanonical base pair, through its amide group, with the displayed cytosine in the template RNA strand, consistent with favipiravir mimicking a guanosine base. The weaker density for the inhibitor, compared to that for the neighboring RNA bases, indicates partial occupancy of the site. The density is most consistent with the inhibitor binding noncovalently to the polymerase, with little to no covalent incorporation. The biochemical assays indicated only minimal incorporation of favipiravir-RTP into the primer under the conditions used to prepare the complex for structural analysis (Fig. 1, lane 11). Density for the α and β phosphates, which are coordinated by two neighboring magnesium ions, can be clearly traced. This density is weaker than that for the pyrazine moiety of favipiravir-RTP; this points to a mixture of possible conformations of the phosphates. Neither the phosphates nor the magnesium ions appear to be coordinated by side chains from the polymerase catalytic site, indicating a mostly "open" conformation of the catalytic site. The density for the favipiravir base appears

discontinuous from the density for the ribose bound to it; however, we verified, using spectroscopy, that the glycosidic bond was stable in conditions used to prepare the complex for cryoEM (*SI Appendix, Fig. S5*). We also observed a weak signal, adjacent to the triphosphate moiety of favipiravir-RTP, consistent with a pyrophosphate molecule (Figs. 3C and 4B). The ³¹P-NMR analysis revealed that the supplied favipiravir-RTP contained pyrophosphate contaminant at approximately equivalent amounts to the favipiravir-RTP inhibitor (*SI Appendix, Fig. S6*). We show that pyrophosphate does not inhibit RdRp activity in the presence of rNTPs (*SI Appendix, Fig. S7*). Pyrophosphate was modeled at this site in the SARS-CoV-2 RdRp nsp12–RNA–remdesivir complex (PDB ID code 7BV2) (10). However, in the influenza RNA polymerase, this site is occupied by the triphosphate of the incoming rNTP [PDB ID code 6SZV (30)]. In contrast, the current structure indicates that favipiravir-RTP is bound at the open RdRp catalytic site in a nonproductive configuration, as discussed below.

We observe signal for the RNA base pairs as synthesized, indicating no translocation of the RNA has occurred in the majority of the intact complexes during the incubation period of 30 min. This supports the interpretation that favipiravir stalls replication by noncovalent interactions at the active site, rather than by covalent incorporation into the replicating strand. Neither base stacking nor base pairing distances in the presence of favipiravir differ from those expected for natural nucleotides. In addition to base pairing with cytosine from the template strand, favipiravir is coordinated by Lys545 in the F1 domain of nsp12, which is positioned to accept hydrogen bonds from the nitrogen atom in the pyrazine ring or donate to the fluorine atom of the inhibitor, although, in both instances, the distances are long (3.4 Å and 3.7 Å, respectively), suggesting possible water-mediated contacts (Fig. 4A). These interactions are potentially functionally important because an arginine substitution of the equivalent residues in the chikungunya virus (CHIKV) and influenza virus H1N1 RdRps is responsible for their decreased susceptibility to favipiravir (2, 31). Two nearby arginines (Arg553 and Arg555) in the nucleoside entry channel are flexible, with no signal visible for the guanidinium group of Arg555 (Fig. 4A). The 2' hydroxyl of the favipiravir nucleotide analogue forms a hydrogen bond to residue Asn691 of nsp12. A serine (Ser682) is positioned, as previously hypothesized (9), to play a role in coordinating the nucleotide for incorporation. The hydrophobic Val557 is stacked against the +1 base in the RNA template.

Discussion

In this study, we determined the cryoEM structure of favipiravir-RTP at the catalytic site of the SARS-CoV-2 RdRp, in complex with template:primer dsRNA, and investigated the influence of this nucleotide analogue inhibitor on RNA synthesis *in vitro*. We observed that favipiravir-RTP is an inefficient




Fig. 4. Coordination of favipiravir-RTP in the active site of the SARS-CoV-2 RdRp. (A) A nonproductive conformation of favipiravir-RTP (F-RTP), base paired to the P+1 nucleotide of the template strand, as shown, was observed in the cryoEM density map. For clarity, the primer strand is omitted, and only the P+1 and P–1 nucleotides of the template strand are shown. (B) The nonproductive conformation may be favored in the presence of pyrophosphate (PPi), which is a possible by-product from the incorporation of rNTPs into the RNA. (C) A hypothetical productive conformation of favipiravir-RTP, which may lead to its incorporation into the primer RNA strand, is modeled. (D) For comparison, the position of an incoming nonhydrolyzable UTP analog in the bat influenza polymerase elongation complex is shown (PDB ID code 6SZV) (30).

substrate for the viral RdRp in primer extension assays, and propose that this is a consequence of a catalytically nonproductive conformation adopted by the drug in the polymerase active site. The nonproductive binding mode of favipiravir-RTP to the catalytic site of RdRp observed here explains the inefficient rate of covalent incorporation in primer extension assays. In the binding mode reported here, the β -phosphate of favipiravir-RTP is not aligned for in-line nucleophilic attack by the 3'OH of the P-1 nucleotide (Fig. 3C and 4A). An optimal geometry would require rotation of the ribose O5'- α P bond by 120°. The structure of a productive influenza polymerase RNA-rNTP complex (PDB ID code 6SZV) (30) showed that the triphosphates of the P+1 nucleotide engage the site possibly occupied by pyrophosphate (the product of rNTP incorporation) in the structure reported here (Fig. 4B and D and *SI Appendix, Fig. S4*). A similar conformation of favipiravir-RTP (Fig. 4C) would allow for the incorporation of favipiravir into the growing RNA primer strand; such a conformation of the phosphates is not consistent with the cryoEM density we observed, in terms of α P- β P distance. Still, the incorporation assay (Fig. 1C, lane 11) demonstrates that a small fraction of the RNA primers in the cryoEM sample are extended by favipiravir incorporation. The incorporation of favipiravir-RTP, albeit inefficient, has been shown to result in lethal mutagenesis to the SARS-CoV-2 genome (13). We therefore expect that there is a small subset of favipiravir-RTP molecules that adopt the productive conformation in the catalytic (+1) site. By cryoEM classification methods, we were unable to separate this subset from the larger subset that contains nonproductively bound favipiravir-RTP, and possibly a subset that contains no favipiravir-RTP at all. This mixture of states resulted in a less resolved, partially fragmented density for the inhibitor in the map (Fig. 3C).

One might hypothesize that pyrophosphate contributes to the slow rate of favipiravir-RTP incorporation by directing the triphosphate moiety of favipiravir-RTP into a nonproductive binding mode. However, pyrophosphate inhibition assays (*SI Appendix, Fig. S7*) indicate that pyrophosphate at concentrations between 10 and 500 μ M does not affect the replication activity of RdRp. We therefore suggest that the nonproductive configuration of favipiravir-RTP is promoted by an intrinsic feature of the favipiravir moiety. One possibility is that water-mediated hydrogen bonds link the fluorine atom of the pyrazine ring to the oxygen atoms of the β -phosphate group to reconfigure the triphosphate into a nonproductive position, although we do not unambiguously identify water molecules bound to favipiravir-RTP in the map at this resolution. In support of this mechanism, T-1105-RTP, which lacks the fluorine, is a more efficient substrate than favipiravir-RTP for SARS-CoV-2 RdRp (13).

While this manuscript was in preparation, another cryoEM reconstruction and an associated atomic structure of the RdRp:dsRNA:favipiravir-RTP complex became publicly available (EMD-30469, PDB ID code 7CTT) (32). This map is distorted along one direction, an artifact characteristic of anisotropic filling of Fourier space in the reconstruction. In contrast to the model described in this work, the alternative map and model suggest a productive conformation of favipiravir-RTP at the catalytic site. These two distinct states—the nonproductive favipiravir-RTP conformation described here, and the productive conformation, reported in ref. 32—may have captured two structural snapshots that account for the slow and inefficient incorporation of favipiravir into the growing RNA strand.

Multiple factors, including complex dissociation, denaturation at the air-water interface, and preferred orientation, impeded our initial attempts for high-resolution structure determination of this complex. We managed to circumvent these by acquiring a large cryoEM dataset and using a combination of HexAuFoil and partially hydrogenated graphene-coated UltrAuFoil EM grids. We make the complete dataset publicly available via the Electron Microscopy Public Image Archive (accession number 10517) in the hope that it will be useful for software development for handling large datasets of structurally heterogeneous cryoEM specimens. For now, cryoEM structure determination of this RdRp-RNA complex in combination with different inhibitors remains far from a routine task. Still, this and other published structures of the complex will aid rational drug design. In the interim, biochemical optimization of the stability of the complex might help yield a specimen that is more stable and randomly oriented in the thin layers of buffer used for cryoEM. This would then make it suitable for rapid structure determination among an array of candidate compounds. The need for a derivatized graphene surface to overcome the strong interactions with the air-water interfaces highlights the problem that surfaces present in cryoEM specimen preparation; further improvements in the specimen preparation process are still needed to enable the high throughput required for drug design and analysis.

The structure reported here suggests at least three possible directions for further efforts toward drug design against the SARS-CoV-2 RdRp. The first is modification of the favipiravir-RTP to bring the α -phosphate into a more favorable conformation for covalent incorporation at the terminus of the extending strand, leading to delayed chain termination and/or more efficient mutagenesis of the viral genome (13). Second, analogs of pyrophosphate bound to the RdRp active site, combined with catalytically inefficient rNTP mimics, might promote a stalled state of the polymerase. Third, modifying the fluorine position or adding other functionalities could make it a better hydrogen bond acceptor. High-resolution structure determination may aid in these directions as new compounds are developed and tested as treatments for COVID-19.

Data Availability. The electron scattering potential map is deposited in the Electron Microscopy Data Bank with accession code [EMD-11692](https://www.ebi.ac.uk/EMDB/entry/EMD-11692), and the atomic model is deposited in the PDB under accession code [PDB ID 7AAP](https://www.rcsb.org/structure/7AAP). The complete, unprocessed cryoEM dataset is deposited in the Electron Microscopy Public Image Archive under code [EMPIAR-10517](https://www.ebi.ac.uk/EMPIAR/entry/EMPIAR-10517).

ACKNOWLEDGMENTS. We thank P. Midgley for enabling access to the Department of Materials Science & Metallurgy of the University of Cambridge for data collection during the pandemic, and S. Scheres for helpful advice during data processing. We also thank J. Grimmett and T. Darling of the Laboratory of Molecular Biology (LMB) Scientific Computing and are grateful to S. Chen, G. Cannone, G. Sharov, A. Yeates, and B. Ahsan of the LMB Electron Microscopy Facility for technical assistance and enabling access to the microscopy facility during the pandemic. This work was supported by a Vice-Chancellor's Award (Cambridge Commonwealth, European and International Trust) and a Bradford scholarship (to K.N.). It was also supported by Medical Research Council Grants MC.UP.120117 (C.J.R.); MC.UP.12016 (D.B.), MRC U105184326, and Wellcome 202754/Z/16/Z (J.L.); MC.UP.A024.1009 (J.D.S.); and Cancer Research UK Grant C576/A14109 (D.B.).

1. L. Buonaguro, M. Tagliamonte, M. L. Tornesello, F. M. Buonaguro, SARS-CoV-2 RNA polymerase as target for antiviral therapy. *J. Transl. Med.* **18**, 185 (2020).
2. R. Abdelnabi *et al.*, Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase. *J. Virol.* **91**, e00487 (2017).
3. S. J. F. Kaptein *et al.*, Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 26955–26965 (2020).
4. C. Chen *et al.*, Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv [Preprint] (2020). <https://doi.org/10.1101/2020.03.17.20037432> (Accessed 1 September 2020).
5. P. Rattanaumpawan, S. Jirajariyavej, K. Lerdlamyong, N. Palavutitotai, J. Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multicenter observational study. medRxiv [Preprint] (2020). <https://doi.org/10.1101/2020.06.24.20133249> (Accessed 1 September 2020).
6. WHO Solidarity Trial Consortium *et al.*, Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv [Preprint] (2020). <https://doi.org/10.1101/2020.10.15.20209817> (Accessed 15 October 2020).
7. R. N. Kirchdoerfer, A. B. Ward, Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nat. Commun.* **10**, 2342 (2019).
8. Y. Gao *et al.*, Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* **368**, 779–782 (2020).
9. H. S. Hillen *et al.*, Structure of replicating SARS-CoV-2 polymerase. *Nature* **584**, 154–156 (2020).
10. W. Yin *et al.*, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* **368**, 1499–1504 (2020).
11. Q. Wang *et al.*, Structural basis for RNA replication by the SARS-CoV-2 polymerase. *Cell* **182**, 417–428.e13 (2020).
12. J. Chen *et al.*, Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. *Cell* **182**, 1560–1573 (2020).
13. A. Shannon *et al.*, Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. *Nat. Commun.* **11**, 4682 (2020).
14. Z. Zhang, J. Yang, D. Barford, Recombinant expression and reconstitution of multiprotein complexes by the USER cloning method in the insect cell-baculovirus expression system. *Methods* **95**, 13–25 (2016).
15. F. W. Studier, Protein production by auto-induction in high-density shaking cultures. *Protein Expr. Purif.* **41**, 207–234 (2005).
16. K. Naydenova, P. Jia, C. J. Russo, Cryo-EM with sub-1 Å specimen movement. *Science* **370**, 223–226 (2020).
17. K. Naydenova, M. J. Peet, C. J. Russo, Multifunctional graphene supports for electron cryomicroscopy. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 11718–11724 (2019).
18. J. R. Bellare, H. T. Davis, L. E. Scriven, Y. Talmon, Controlled environment vitrification system: An improved sample preparation technique. *J. Electron. Microsc. Tech.* **10**, 87–111 (1988).
19. C. J. Russo, S. S. Scotcher, M. Kyte, A precision cryostat design for manual and semi-automated cryo-plunge instruments. *Rev. Sci. Instrum.* **87**, 114302 (2016).

20. J. Zivanov *et al.*, New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* **7**, e42166 (2018).
21. T. Wagner *et al.*, SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. *Commun. Biol.* **2**, 218 (2019).
22. J. Zivanov, T. Nakane, S. H. W. Scheres, A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. *IUCrJ* **6**, 5–17 (2019).
23. K. Naydenova, C. J. Russo, Measuring the effects of particle orientation to improve the efficiency of electron cryomicroscopy. *Nat. Commun.* **8**, 629 (2017).
24. K. Ramlaul, C. M. Palmer, T. Nakane, C. H. Aylett, Mitigating local over-fitting during single particle reconstruction with SIDESPLITTER. *J. Struct. Biol.* **211**, 107545 (2020).
25. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **66**, 486–501 (2010).
26. A. Casañal, B. Lohkamp, P. Emsley, Current developments in Coot for macromolecular model building of electron cryo-microscopy and crystallographic data. *Protein Sci.* **29**, 1055–1064 (2020).
27. D. Liebschner *et al.*, Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. *Acta Crystallogr. D* **75**, 861–877 (2019).
28. H. Sangawa *et al.*, Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. *Antimicrob. Agents Chemother.* **57**, 5202–5208 (2013).
29. A. Arias, L. Thorne, I. Goodfellow, Favipiravir elicits antiviral mutagenesis during virus replication in vivo. *eLife* **3**, e03679 (2014).
30. J. M. Wandzik *et al.*, A structure-based model for the complete transcription cycle of influenza polymerase. *Cell* **181**, 877–893.e21 (2020).
31. D. H. Goldhill *et al.*, The mechanism of resistance to favipiravir in influenza. *Proc. Natl. Acad. Sci. U.S.A.* **115**, 11613–11618 (2018).
32. Q. Peng *et al.*, Structural basis of SARS-CoV-2 polymerase inhibition by Favipiravir. *bioRxiv* [Preprint] (2020). <https://doi.org/10.1101/2020.10.19.345470> (Accessed 19 October 2020).